Hypokalaemia in pregnant women treated with the beta 2-mimetic drug fenoterol--a concentration and time dependent effect.
The effect of tocolytic treatment with fenoterol on plasma potassium concentrations was studied in 83 pregnant women on intravenous tocolytic therapy. Plasma concentrations of fenoterol and potassium were measured simultaneously, the time interval between initiation of therapy and taking the blood sample varying from 2 hours to 100 days. In a subset of 13 patients this blood sample was taken after two hours of therapy and pretreatment potassium concentrations were measured also. Pretreatment potassium concentrations were normal in these 13 patients and declined to 2.88 mmol/L (median) fenoterol concentrations being 320 ng/L through 1164 ng/L. Potassium concentrations measured later than 24 hours after initiation of therapy were all in the normal range corresponding fenoterol concentrations varying from 200 ng/L to 2504 ng/L. The multivariate statistical model for the description of all data showed that the duration of treatment was the only variable which explained the data to a significant extent. This might indicate that tolerance to the potassium lowering effect of fenoterol had developed within 24 hours after initiation of therapy. In the subset of 13 patients pretreatment potassium concentrations were found to be more important in explaining potassium concentrations than fenoterol concentrations at two hours. As we did not observe any adverse events in patients with low potassium concentrations and potassium concentrations were normal within 24 hours, we conclude that hypokalaemia due to fenoterol in the treatment of premature labor is not of clinical concern.
Hildebrandt
R
R
Department Obstetrics and Gynecology, University Hospital Klinikum Benjamin Franklin, Free University Berlin, Fed. Rep. of Germany.
Weitzel
H K
HK
Gundert-Remy
U
U
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D005260:Female; D005280:Fenoterol / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced*; D007262:Infusions, Intravenous; D009994:Osmolar Concentration; D011188:Potassium / Q000097:blood / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced*; D013997:Time Factors; D015149:Tocolytic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D015149:Tocolytic Agents; D005280:Fenoterol; D011188:Potassium